Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Phase 3

Completed

• Conditions: Hidradenitis Suppurativa
• Interventions: Drug: adalimumab

• Registration Number: NCT02904902
• Lead Sponsor: AbbVie

Brief Summary

This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).

Detailed Description

Prior to initiation of this study, global Phase 2b study and pivotal Phase III studies were completed in the Western countries and market authorization of adalimumab was approved in United States (US) and European Union (EU) for the treatment of subjects with HS. The differences between this study and global studies include sample size, study design, duration, and race.

Study Timeline

• Study Start: 2016-09-06
• Study First Submitted: 2016-09-14
• Study First Submitted QC: 2016-09-14
• Study First Posted: 2016-09-19
• Primary Completion: 2017-09-01
• Results First Submitted: 2018-08-09
• Results First Submitted QC: 2018-10-25
• Results First Posted: 2019-02-27
• Study Completion: 2019-05-30
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-30
• Last Update Posted: 2020-05-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Participant must have a diagnosis of HS;
• Participant must have any HS symptom at least 6 months prior to Baseline;
• HS lesions must be present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III;
• Participant must have stable HS for at least 2 months (60 days) prior to Screening and also at the Baseline visit;
• Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit.

Exclusion Criteria

• Prior treatment with adalimumab or other anti-tumor necrosis factor (TNF) therapy or participation in adalimumab trial;
• Any other active skin lesion or condition that may interfere with assessment of HS;
• Participants received antibiotic treatment for HS within 28 days prior to the Baseline visit other than those allowed per protocol. Participant on permitted oral antibiotic treatment (doxycycline or minocycline only) for HS who have not been on a stable dose for at least 28 days prior to the Baseline visit;
• Participants received prescription topical therapies for the treatment for HS within 14 days prior to the Baseline visit;
• Participants received systemic non-biologic therapies with potential therapeutic impact for HS less than 28 days prior to the Baseline visit;
• Participants received oral concomitant analgesics (non-opioids and opioids) for HS-related pain within 14 days prior to the Baseline visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Adalimumab	adalimumab	Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12	Week 12	HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Achieving AN Count of 0, 1, or 2 at Week 12	Week 12	The percentage of participants with AN counts lowered to 0, 1, or 2 at Week 12.
Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3	Week 0 (Baseline), Week 2	The participant's Global Assessment of Skin Pain NRS was used to assess the worst skin pain due to HS. Scores range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours."
Change From Baseline to Week 12 in Modified Sartorius Scale Score	Baseline (last non-missing value on or before the date of first dose of study drug), Week 2, Week 4, Week 8, Week 12	The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

Trial Locations

Locations (8)

Fukuoka University Hospital /ID# 151350; 🇯🇵 Fukuoka, Japan

Takagi Dermatological Clinic /ID# 151906; 🇯🇵 Obihiro, Hokkaido, Japan

Kurume University Hospital /ID# 152579; 🇯🇵 Kurume-shi, Fukuoka, Japan

NHO Osaka National Hosp /ID# 152452; 🇯🇵 Osaka-shi, Osaka, Japan

Nagoya City University Hospital /ID# 151495; 🇯🇵 Nagoya-shi, Aichi, Japan

Tokai University Hachioji Hosp /ID# 151338; 🇯🇵 Hachioji, Tokyo, Japan

University of the Ryukyus Hosp /ID# 152268; 🇯🇵 Nakagami-gun, Okinawa, Japan

Tokyo Medical University Hospital /ID# 154171; 🇯🇵 Shinjuku-ku, Tokyo, Japan